Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications

dc.contributor.authordos Santos, Giovanny Carvalho [UNESP]
dc.contributor.authorMartins, Lucas Michelão [UNESP]
dc.contributor.authorBregadiolli, Bruna Andressa [UNESP]
dc.contributor.authorMoreno, Vitor Fernandes [UNESP]
dc.contributor.authorda Silva-Filho, Luiz Carlos [UNESP]
dc.contributor.authorda Silva, Bruno Henrique Sacoman Torquato
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Federal de Uberlândia (UFU)
dc.date.accessioned2022-04-28T19:42:46Z
dc.date.available2022-04-28T19:42:46Z
dc.date.issued2021-01-01
dc.description.abstractA virus outbreak challenges the economic, medical, and public health infrastructure worldwide. More than one virus capable of triggering diseases have been identified per year since 1972, which requires the development of new ways of treatment and prevention, however, such processes are not rapid and easy. With the pandemic scenario experienced since early 2020, several drugs with well-known purposes have gained prominence, due to speculation of their use in the treatment against the new coronavirus. Among the main drugs studied, the vast majority contain a heterocyclic structure. In this review, we presented the traditional and efficient synthesis of 15 drugs that have been studied for the COVID-19 treatment, containing in their structure heterocycles like indole, quinoline, pyrimidone, tetrahydrofuran, pyrrolidine, triazole, pyridazine, pyrazole, pyrrolopyrimidine, azetidine, pyrrolotriazine, pyrazine, tetrahydropyran, benzofuran, spiroketal, and thiazole. Furthermore, we have shown the original applications, as well as their structure–activity relationship and what is their situation as a drug candidate against COVID-19. Thus, the objective was to consolidate the main synthetic and pharmacological aspects involving clinically developed heterocycles that at some point were presented as promising against SARS-CoV-2.en
dc.description.affiliationSchool of Sciences Department of Chemistry São Paulo State University (UNESP)
dc.description.affiliationInstitute of Chemistry São Paulo State University (UNESP)
dc.description.affiliationInstitute of Chemistry Federal University of Uberlandia (UFU)
dc.description.affiliationUnespSchool of Sciences Department of Chemistry São Paulo State University (UNESP)
dc.description.affiliationUnespInstitute of Chemistry São Paulo State University (UNESP)
dc.identifierhttp://dx.doi.org/10.1002/jhet.4349
dc.identifier.citationJournal of Heterocyclic Chemistry.
dc.identifier.doi10.1002/jhet.4349
dc.identifier.issn1943-5193
dc.identifier.issn0022-152X
dc.identifier.scopus2-s2.0-85112289157
dc.identifier.urihttp://hdl.handle.net/11449/222174
dc.language.isoeng
dc.relation.ispartofJournal of Heterocyclic Chemistry
dc.sourceScopus
dc.subjectantiviral
dc.subjectheterocycles
dc.subjectSAR
dc.subjectsynthesis
dc.titleHeterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applicationsen
dc.typeResenha
unesp.author.orcid0000-0002-4568-9492[2]
unesp.author.orcid0000-0001-6235-6246[3]
unesp.author.orcid0000-0002-4325-5674[4]
unesp.author.orcid0000-0001-6674-2160[5]
unesp.author.orcid0000-0003-0261-1035[6]

Arquivos

Coleções